

Resource Summary Report

Generated by [dkNET](#) on Sep 3, 2026

CD45

RRID:AB_396774

Type: Antibody

Proper Citation

BD Biosciences Cat# 557659, RRID:AB_396774

Antibody Information

URL: http://antibodyregistry.org/AB_396774

Proper Citation: BD Biosciences Cat# 557659, RRID:AB_396774

Target Antigen: CD45

Host Organism: rat

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD45

Description: This monoclonal targets CD45

Target Organism: mouse

Antibody ID: AB_396774

Vendor: BD Biosciences

Catalog Number: 557659

Record Creation Time: 20231110T081132+0000

Record Last Update: 20260829T020100+0000

Ratings and Alerts

No rating or validation information has been found for CD45.

No alerts have been found for CD45.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 122 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Munoz MA, et al. (2026) NK cell dysfunction and interferon- γ production underlie autoinflammation in mevalonate kinase deficiency. *Immunity*, 59(6), 1726.

Huang L, et al. (2026) Engineered Akkermansia muciniphila vesicles for targeted pyroptosis and trained immunity to enhance immunotherapy in hepatocellular carcinoma. *Cell reports. Medicine*, 7(1), 102524.

Hasegawa M, et al. (2026) Tolerance to extracellular acidic pH facilitates tumor plasticity. *Cell reports*, 117226.

Lei J, et al. (2026) Metabolically engineered probiotic OMVs as nanovaccine mediating sequential immunomodulation for chronic bone infection immunotherapy. *Cell reports. Medicine*, 7(6), 102842.

Ta N, et al. (2026) Targeting p21-High Senescent Kupffer Cells Nanotherapeutically Potentiates Antitumor Immunity in Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e76384.

Qian P, et al. (2026) Palmitic acid reprograms neutrophils to compromise vascular integrity and promote breast cancer lung metastasis. *Immunity*, 59(7), 1964.

McCourt B, et al. (2026) C9orf72 in myeloid cells prevents an inflammatory response to microbial glycogen. *Cell reports*, 45(2), 116906.

Luo Y, et al. (2026) CCL5 deficiency aggravates acute DSS-induced colitis by restricting IL-33-induced formation of Tregs in intestinal tract. *Clinical science (London, England : 1979)*, 140(1).

Lu G, et al. (2026) In vivo detection of immune responses via cytokine activity labeling. *Cell*.

Yoshimura S, et al. (2026) Genomic Subtype Influences BH3 Mimetic Drug Sensitivity and Synergy with Cytotoxic Chemotherapeutics in T-cell Acute Lymphoblastic Leukemia. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(14), 3018.

Dai W, et al. (2026) An IGF2BP3-dependent metabolic circuit governs macrophage recruitment and immunosuppression in glioblastoma. *Cell reports*, 45(7), 117643.

Yao L, et al. (2026) Nilotinib induces immunogenic cuproptosis to potentiate cancer immunotherapy. *Cell reports. Medicine*, 102928.

Wang Y, et al. (2026) A combined strategy of EGFR-MET bispecific antibody and HER3 ADC to overcome osimertinib resistance in NSCLC. *Cellular oncology (Dordrecht, Netherlands)*, 49(1), 31.

Yang-Jensen SK, et al. (2026) Microbial activation of the GLP-2R mitigates gastrointestinal inflammation. *Nature communications*, 17(1), 1839.

Zou W, et al. (2026) MSCs delivering LIGHT prime immune response against CAFs to harness antigen loss variants. *Cancer gene therapy*, 33(4), 405.

Kim TY, et al. (2026) Newly isolated human-derived *Lactobacillus fermentum* strain stimulates IFN- γ -secreting CD8⁺ T cells for enhanced anti-cancer immunity. *iScience*, 29(5), 115642.

Li X, et al. (2026) FBXO3-mediated DUSP9 ubiquitination promotes leukemia stem cell maintenance and tyrosine kinase inhibitor resistance in chronic myeloid leukemia. *Cell reports. Medicine*, 7(3), 102686.

Yang Z, et al. (2026) Macrophage-mediated brain-bone marrow crosstalk promotes chronic stress-induced glioma growth. *Cancer cell*.

Wu HL, et al. (2025) DHDH-mediated D-xylose metabolism induces immune evasion in triple-negative breast cancer. *Med (New York, N.Y.)*, 6(3), 100535.

Song W, et al. (2025) Targeting the UFL1-PARP1 axis amplifies anti-tumor immunity. *Cell reports*, 44(10), 116433.